Synopsis
Objectives The extended half-life of dalbavancin justifies a once-a-week dosing schedule and is supposed to favour early discharge. These advantages may therefore compensate for the cost of dalbavancin. We aimed to assess the real-life budget impact of dalbavancin through its impact on the length of stay in French hospitals.
Methods A multicentre cohort based on the French registry of dalbavancin use in 2019 was compared to the French national discharge summary database. Lengths of stay and budget impact related to the infection type, the time of introduction of dalbavancin, the type of catheter and patient subgroups were assessed. An early switch was defined when dalbavancin was administered as the first or second treatment and within less than 11 days of hospitalization.
Results One hundred seventy-nine patients were identified in the registry, and 154 were included in our study. Dalbavancin is mostly used for bone and joint infections, infective endocarditis and acute bacterial skin and skin structure infections. When compared to the data for similar patients in the national database, the length of stay was almost always shorter for patients treated with dalbavancin. The budget impact for dalbavancin was heterogeneous but frequently generated savings. Early switching was associated with savings (or lesser costs). Patients who required a deep venous catheter and those with the most severe patients benefited the most from dalbavancin.
Conclusions Our study confirms that dalbavancin is associated with early discharge, which can offset its cost and generate savings. The greatest benefit is achieved with an early switch.
Competing Interest Statement
Transparency declarations: The analysis of the UNIHA cohort was conducted by PHE and was funded by Correvio. A.V. and M.B. are employed by PHE. All other authors: none to declare.
Funding Statement
Fundings: This work was supported by a grant from Correvio to Public Health Expertise (PHE), where A.V. and M.B. are employed. English editing of the manuscript by AJE has been funded by Correvio. Correvio had no other role than funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
A retrospective analyze of the data of patients with Dalbavancin in 2019 was performed. 179 evaluations and or data were gathered. According to French law on ethics, patients were informed that their codified data will be used for the study. According to the French ethic and regulatory law (public health code) retrospective studies based on the exploitation of usual care data don't should be submit at an ethic comitee but they have to be declared or covered by reference methodology of the French National Commission for Informatics and Liberties (CNIL). A collection and computer processing of personal and medical date was implemented to analyze the results of the research. CORREVIO SAS signed a commitment of compliance to the reference methodology MR004 of the French National Commission for Informatics and Liberties (CNIL). After evaluation and validation by the data protection officer and according to the General Data Protection Regulation (1), this study completing all the criteria, it is register in the register of retrospective study of CORREVIO SAS (and cover by the MR004 (CNIL : MR004:2213417). This study was approved by CORREVIO SAS and confirm that ethic requirements were totally respected in the above report. (1) Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data were all public
